# Efficacy and Safety of Chidamide in CBF Leukemia

> **NCT03031262** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 250 (estimated)

## Conditions studied

- AML

## Interventions

- **DRUG:** Cytarabine
- **DRUG:** Chidamide

## Key facts

- **NCT ID:** NCT03031262
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-02-08
- **Primary completion:** 2025-04-10
- **Final completion:** 2027-12-30
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03031262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03031262, "Efficacy and Safety of Chidamide in CBF Leukemia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03031262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*